Cardiff Oncology will Present New Data from Lead Clinical Program in KRAS-mutated Colorectal Cancer

4:00 pm - 5:00 pm EDT

Cardiff Oncology will present new data from its lead clinical program evaluating onvansertib in combination with standard-of-care FOLFIRI/bevacizumab for the second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC). The upcoming virtual event will feature the clinical trial principal investigator, Heinz-Josef Lenz, M.D., FACP (USC Norris Comprehensive Cancer Center), and key clinical advisor Afsaneh Barzi, M.D., Ph.D., (City of Hope Comprehensive Cancer Center).